ArticleFrontiers in immunology2025
The impact of different immunosuppressants and acute immune rejection on clinical outcomes in diverse solid organ transplant recipients.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Epstein-Barr Virus Donor Serostatus on Post-Transplant Mortality and Post-Transplant Lymphoproliferative Disorder in Epstein-Barr Virus Seropositive Thoracic Organ Transplant Recipients: Data from the Organ Procurement and Transplantation Network.Journal of medical virology · 2026Article
- Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of solid organ transplantation (SOT) and the use of immunosuppressants provide patients with terminal conditions hope. Acute immune rejection (AR) in SOT patients, however, has become more noticeable. Our study examined the relationship between AR and patient survival in a variety of organ transplants, including liver, kidney, heart, lung, pancreas, intestine, combined heart-lung, and pancreas-kidney transplantations, using the Scientific Registry of Transplant Recipients (SRTR) database. Our research showed that AR universally reduces survival across all solid organ transplant types. Immunosuppressants exhibit organ-specific efficacy patterns, with divergent impacts on survival and AR risk. For instance, in liver transplants (LT), generic tacrolimus increased AR risk (OR: 1.31; 95% CI: 1.21-1.42), while AZA reduced it (OR: 0.52; 95% CI: 0.44-0.60). In kidney transplants (KT), tacrolimus increased AR risk (OR: 1.24; 95% CI: 1.2-1.28), whereas Cyclosporin reduced it (OR: 0.47; 95% CI: 0.43-0.52). Furthermore, the same immunosuppressant can have varying effects on survival across transplant types; MMF significantly increased the risk of death in LT, HT, LU, KT, HL, and PK patients, but reduced the risk of death in PT patients. Originator and generic immunosuppressants differentially influence survival outcomes and rejection incidence. For example, in heart transplantation (HT), originator cyclosporine improved survival, while generic cyclosporine (EON) was associated with decreased survival and increased AR risk. Overall, our research offers a thorough and methodical evaluation of how various immunosuppressants affect prognosis and how AR affects the survival of patients receiving different kinds of SOT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.